Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests

  The 66th American Society for Hematology (ASH) Annual Meeting and Exhibition took place from December 7-10, 2023. During the meeting, researchers and other stakeholders shared insights into clinical trends,…

Continue Reading Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests
Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients
source: shutterstock.com

Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients

The treatment of young patients with R/R acute myeloid leukemia (AML) poses a challenge for clinicians. Chemotherapy regimens, such as high doses of cytarabine, fludarabine, and other salvage reduction therapies,…

Continue Reading Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients
Bexmarilimab for AML Granted Orphan Drug Designation
https://pixabay.com/en/hands-teamwork-team-spirit-cheer-up-1939895/

Bexmarilimab for AML Granted Orphan Drug Designation

Currently available therapeutics may not be adequately effective in the fight to treat late-stage acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers and drug developers are working to identify…

Continue Reading Bexmarilimab for AML Granted Orphan Drug Designation
FDA Lifts Clinical Hold on Phase 1 AML and MDS Clinical Trial
source: pixabay.com

FDA Lifts Clinical Hold on Phase 1 AML and MDS Clinical Trial

Effective June 1, 2023, the FDA lifted its clinical hold on Foghorn Therapeutics’ Phase 1 study of FHD-286 dose escalation in patients with acute myeloid leukemia and myelodysplastic syndromes. The…

Continue Reading FDA Lifts Clinical Hold on Phase 1 AML and MDS Clinical Trial
New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
source: pixabay.com

New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant

  Omisirge (omidubicel) is the first allogeneic (from a donor) product for SCT that has been the recipient of FDA approval. The FDA's nod moves Omisirge into the realm of…

Continue Reading New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results
source: pixabay.com

Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results

  For patients with refractory or relapsed KMT2A rearrangement or NPM1-mutations, the AUGMENT 101 study of the investigational menin inhibitor revumenib yielded impressive results. According to an article in MedicalXpress,…

Continue Reading Advanced Leukemia: Test of Oral Revumenib Brought Impressive Results
Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
source: pixabay.com

Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

  Researchers acknowledge that the primary cause of failure of stem cell transplants is disease relapse. This holds true specifically for allogeneic hematopoietic stem cell transplants where a cancer patient…

Continue Reading Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy
source: pixabay.com

FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

The FDA has just provided AB001 the Orphan Drug designation for both acute myeloid leukemia (AML) and pancreatic cancer. This small molecule was developed by Vopec Pharmaceuticals and Agastiya Biotech.…

Continue Reading FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy

Karyopharm Therapeutics has just announced that Eltanexor, their investigative therapy for myelodysplastic syndromes (MDS), has been given Orphan Drug Designation by the FDA. This designation means that the FDA believes…

Continue Reading FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy